Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 178

1.

Resveratrol Sustains Insulin-Degrading Enzyme Activity toward Aβ42.

Krasinski CA, Ivancic VA, Zheng Q, Spratt DE, Lazo ND.

ACS Omega. 2018 Oct 31;3(10):13275-13282. doi: 10.1021/acsomega.8b01913. Epub 2018 Oct 16.

2.

Transcriptomic heterogeneity in multifocal prostate cancer.

Salami SS, Hovelson DH, Kaplan JB, Mathieu R, Udager AM, Curci NE, Lee M, Plouffe KR, de la Vega LL, Susani M, Rioux-Leclercq N, Spratt DE, Morgan TM, Davenport MS, Chinnaiyan AM, Cyrta J, Rubin MA, Shariat SF, Tomlins SA, Palapattu GS.

JCI Insight. 2018 Nov 2;3(21). pii: 123468. doi: 10.1172/jci.insight.123468. [Epub ahead of print]

3.

Genomic Hallmarks and Structural Variation in Metastatic Prostate Cancer.

Quigley DA, Dang HX, Zhao SG, Lloyd P, Aggarwal R, Alumkal JJ, Foye A, Kothari V, Perry MD, Bailey AM, Playdle D, Barnard TJ, Zhang L, Zhang J, Youngren JF, Cieslik MP, Parolia A, Beer TM, Thomas G, Chi KN, Gleave M, Lack NA, Zoubeidi A, Reiter RE, Rettig MB, Witte O, Ryan CJ, Fong L, Kim W, Friedlander T, Chou J, Li H, Das R, Li H, Moussavi-Baygi R, Goodarzi H, Gilbert LA, Lara PN Jr, Evans CP, Goldstein TC, Stuart JM, Tomlins SA, Spratt DE, Cheetham RK, Cheng DT, Farh K, Gehring JS, Hakenberg J, Liao A, Febbo PG, Shon J, Sickler B, Batzoglou S, Knudsen KE, He HH, Huang J, Wyatt AW, Dehm SM, Ashworth A, Chinnaiyan AM, Maher CA, Small EJ, Feng FY.

Cell. 2018 Oct 18;175(3):889. doi: 10.1016/j.cell.2018.10.019. No abstract available.

4.

Association of Gleason Grade With Androgen Deprivation Therapy Duration and Survival Outcomes: A Systematic Review and Patient-Level Meta-analysis.

Kishan AU, Wang X, Seiferheld W, Collette L, Sandler KA, Sandler HM, Bolla M, Maingon P, De Reijke T, Hanks GE, Nickols NG, Rettig M, Drakaki A, Reiter RE, Spratt DE, Kupelian PA, Steinberg ML, King CR.

JAMA Oncol. 2018 Sep 20. doi: 10.1001/jamaoncol.2018.3732. [Epub ahead of print]

PMID:
30326032
5.

The Immune Landscape of Prostate Cancer and Nomination of PD-L2 as a Potential Therapeutic Target.

Zhao SG, Lehrer J, Chang SL, Das R, Erho N, Liu Y, Sjöström M, Den RB, Freedland SJ, Klein EA, Karnes RJ, Schaeffer EM, Xu M, Speers C, Nguyen PL, Ross AE, Chan JM, Cooperberg MR, Carroll PR, Davicioni E, Fong L, Spratt DE, Feng FY.

J Natl Cancer Inst. 2018 Oct 13. doi: 10.1093/jnci/djy141. [Epub ahead of print]

PMID:
30321406
6.

Enzyme kinetics from circular dichroism of insulin reveals mechanistic insights into the regulation of insulin-degrading enzyme.

Ivancic VA, Krasinski CA, Zheng Q, Meservier RJ, Spratt DE, Lazo ND.

Biosci Rep. 2018 Nov 7;38(6). pii: BSR20181416. doi: 10.1042/BSR20181416. Print 2018 Dec 21.

PMID:
30305381
7.

Association of ERG/PTEN status with biochemical recurrence after radical prostatectomy for clinically localized prostate cancer.

Mehra R, Salami SS, Lonigro R, Bhalla R, Siddiqui J, Cao X, Spratt DE, Palapattu GS, Palanisamy N, Wei JT, Chinnaiyan AM, Tomlins SA.

Med Oncol. 2018 Oct 5;35(12):152. doi: 10.1007/s12032-018-1212-6.

PMID:
30291535
8.

Evidence-based Risk Stratification to Guide Hormone Therapy Use With Salvage Radiation Therapy for Prostate Cancer.

Spratt DE.

Int J Radiat Oncol Biol Phys. 2018 Nov 1;102(3):556-560. doi: 10.1016/j.ijrobp.2018.06.037. No abstract available.

PMID:
30238901
9.

Management of Biochemically Recurrent Prostate Cancer: Ensuring the Right Treatment of the Right Patient at the Right Time.

Spratt DE, McHugh DJ, Morris MJ, Morgans AK.

Am Soc Clin Oncol Educ Book. 2018 May 23;(38):355-362. doi: 10.1200/EDBK_200319.

10.

1H, 13C, and 15N resonance assignments of the C-terminal lobe of the human HECT E3 ubiquitin ligase ITCH.

Beasley SA, Bardhi R, Spratt DE.

Biomol NMR Assign. 2018 Sep 18. doi: 10.1007/s12104-018-9843-2. [Epub ahead of print]

PMID:
30229450
11.

Genomics, bio specimens, and other biological data: Current status and future directions.

Rosenstein BS, Rao A, Moran JM, Spratt DE, Mendonca MS, Al-Lazikani B, Mayo CS, Speers C.

Med Phys. 2018 Oct;45(10):e829-e833. doi: 10.1002/mp.12912. Epub 2018 Sep 18. No abstract available.

PMID:
30226926
12.

Reply to A.J. Chang et al and A. Gomez-Iturriaga et al.

Spratt DE, Carroll PC.

J Clin Oncol. 2018 Sep 13:JCO1800799. doi: 10.1200/JCO.18.00799. [Epub ahead of print] No abstract available.

PMID:
30212290
13.

International multi-center validation of an intermediate-risk subclassification of prostate cancer treated with radical treatment without hormone therapy.

Berlin A, Moraes FY, Sanmamed N, Glicksman R, Koven A, Espin-Garcia O, Leite ETT, Silva JLF, Gadia R, Nesbitt M, Catton CN, Kaffenberger S, Salami SS, Morgan TM, Hearn JWD, Jackson WC, Mehra R, Chung P, Fleshner NE, Zumsteg ZS, Dess RT, Feng FY, Finelli A, Spratt DE.

J Urol. 2018 Aug 25. pii: S0022-5347(18)43782-2. doi: 10.1016/j.juro.2018.08.044. [Epub ahead of print]

PMID:
30153435
14.

Are we inadvertently widening the disparity gap in pursuit of precision oncology?

Spratt DE.

Br J Cancer. 2018 Oct;119(7):783-784. doi: 10.1038/s41416-018-0223-6. Epub 2018 Aug 21. No abstract available.

PMID:
30131549
15.

Predominance of Spinal Metastases Involving the Posterior Vertebral Body.

Guo M, Kolberg KL, Smith EC, Smith BW, Yousif JE, Kessler JL, Linzey JR, Calinescu AA, Clines GA, Spratt DE, Szerlip NJ.

World Neurosurg. 2018 Nov;119:e991-e996. doi: 10.1016/j.wneu.2018.08.029. Epub 2018 Aug 13.

PMID:
30114534
16.

The Longest Amyloid-β Precursor Protein Intracellular Domain Produced with Aβ42 Forms β-Sheet-Containing Monomers That Self-Assemble and Are Proteolyzed by Insulin-Degrading Enzyme.

Krasinski CA, Zheng Q, Ivancic VA, Spratt DE, Lazo ND.

ACS Chem Neurosci. 2018 Aug 3. doi: 10.1021/acschemneuro.8b00305. [Epub ahead of print]

PMID:
30067897
17.

Genomic biomarkers in prostate cancer.

Kornberg Z, Cooperberg MR, Spratt DE, Feng FY.

Transl Androl Urol. 2018 Jun;7(3):459-471. doi: 10.21037/tau.2018.06.02. Review.

18.

Medulloblastoma therapy generates risk of a poorly-prognostic H3 wild-type subgroup of diffuse intrinsic pontine glioma: a report from the International DIPG Registry.

Gits HC, Anderson M, Stallard S, Pratt D, Zon B, Howell C, Kumar-Sinha C, Vats P, Kasaian K, Polan D, Matuszak M, Spratt DE, Leonard M, Qin T, Zhao L, Leach J, Chaney B, Escorza NY, Hendershot J, Jones B, Fuller C, Leary S, Bartels U, Bouffet E, Yock TI, Robertson P, Mody R, Venneti S, Chinnaiyan AM, Fouladi M, Gottardo NG, Koschmann C.

Acta Neuropathol Commun. 2018 Jul 26;6(1):67. doi: 10.1186/s40478-018-0570-9.

19.

Genomic Hallmarks and Structural Variation in Metastatic Prostate Cancer.

Quigley DA, Dang HX, Zhao SG, Lloyd P, Aggarwal R, Alumkal JJ, Foye A, Kothari V, Perry MD, Bailey AM, Playdle D, Barnard TJ, Zhang L, Zhang J, Youngren JF, Cieslik MP, Parolia A, Beer TM, Thomas G, Chi KN, Gleave M, Lack NA, Zoubeidi A, Reiter RE, Rettig MB, Witte O, Ryan CJ, Fong L, Kim W, Friedlander T, Chou J, Li H, Das R, Li H, Moussavi-Baygi R, Goodarzi H, Gilbert LA, Lara PN Jr, Evans CP, Goldstein TC, Stuart JM, Tomlins SA, Spratt DE, Cheetham RK, Cheng DT, Farh K, Gehring JS, Hakenberg J, Liao A, Febbo PG, Shon J, Sickler B, Batzoglou S, Knudsen KE, He HH, Huang J, Wyatt AW, Dehm SM, Ashworth A, Chinnaiyan AM, Maher CA, Small EJ, Feng FY.

Cell. 2018 Jul 26;174(3):758-769.e9. doi: 10.1016/j.cell.2018.06.039. Epub 2018 Jul 19. Erratum in: Cell. 2018 Oct 18;175(3):889.

20.

Frequent PD-L1 Protein Expression and Molecular Correlates in Urinary Bladder Squamous Cell Carcinoma.

Udager AM, McDaniel AS, Hovelson DH, Fields K, Salami SS, Kaffenberger SD, Spratt DE, Montgomery JS, Weizer AZ, Reichert ZR, Alva AS, Chinnaiyan AM, Tomlins SA, Mehra R.

Eur Urol. 2018 Oct;74(4):529-531. doi: 10.1016/j.eururo.2018.06.019. Epub 2018 Jul 3. No abstract available.

PMID:
29980330
21.

Clinical Outcomes for Patients With Gleason Score 10 Prostate Adenocarcinoma: Results From a Multi-institutional Consortium Study.

Sandler KA, Cook RR, Ciezki JP, Ross AE, Pomerantz MM, Nguyen PL, Shaikh T, Tran PT, Stock RG, Merrick GS, Demanes DJ, Spratt DE, Abu-Isa EI, Wedde TB, Lilleby W, Krauss DJ, Shaw GK, Alam R, Reddy CA, Song DY, Klein EA, Stephenson AJ, Tosoian JJ, Hegde JV, Yoo SM, Fiano R, D'Amico AV, Nickols NG, Aronson WJ, Sadeghi A, Greco SC, Deville C, McNutt T, DeWeese TL, Reiter RE, Said JW, Steinberg ML, Horwitz EM, Kupelian PA, King CR, Kishan AU.

Int J Radiat Oncol Biol Phys. 2018 Jul 15;101(4):883-888. doi: 10.1016/j.ijrobp.2018.03.060. Epub 2018 Apr 5.

PMID:
29976500
22.

Surgical Approach to Bone Metastases.

Siegel GW, Biermann JS, Calinescu AA, Spratt DE, Szerlip NJ.

Curr Osteoporos Rep. 2018 Jun 18. doi: 10.1007/s11914-018-0463-7. [Epub ahead of print] Review.

PMID:
29915966
23.

Transcriptomic Heterogeneity of Favorable-risk Prostate Cancer: Time To Move Past Cancer of the Prostate Risk Assessment (CAPRA) to Clinical-genomic Risk.

Spratt DE, Schaeffer EM.

Eur Urol. 2018 Oct;74(4):453-454. doi: 10.1016/j.eururo.2018.06.001. Epub 2018 Jun 12. No abstract available.

PMID:
29907357
24.

Mentorship Experiences of Early-Career Academic Radiation Oncologists in North America.

Lalani N, Griffith KA, Jones RD, Spratt DE, Croke J, Jagsi R.

Int J Radiat Oncol Biol Phys. 2018 Jul 1;101(3):732-740. doi: 10.1016/j.ijrobp.2018.03.035. Epub 2018 Mar 30.

PMID:
29893281
25.

Ki-67 Remains Solely a Prognostic Biomarker in Localized Prostate Cancer.

Spratt DE.

Int J Radiat Oncol Biol Phys. 2018 Jul 1;101(3):513-515. doi: 10.1016/j.ijrobp.2018.03.008. No abstract available.

PMID:
29893267
26.

The relationship of study and authorship characteristics on trial sponsorship and self-reported conflicts of interest among neuro-oncology clinical trials.

Raman S, Moraes FY, Mendez LC, Taunk NK, Suh JH, Souhami L, Slotman B, Kongkham P, Spratt DE, Berlin A, Marta GN.

J Neurooncol. 2018 Aug;139(1):195-203. doi: 10.1007/s11060-018-2860-2. Epub 2018 Jun 4.

PMID:
29869023
27.

Optimal Radical Therapy for Localized Prostate Cancer: Recreation of the Self-Fulfilling Prophecy With Combination Brachytherapy?

Spratt DE, Carroll PR.

J Clin Oncol. 2018 Oct 10;36(29):2914-2917. doi: 10.1200/JCO.2018.78.6236. Epub 2018 May 21. No abstract available.

PMID:
29782208
28.

Development and Validation of a Prostate Cancer Genomic Signature that Predicts Early ADT Treatment Response Following Radical Prostatectomy.

Karnes RJ, Sharma V, Choeurng V, Ashab HA, Erho N, Alshalalfa M, Trock B, Ross A, Yousefi K, Tsai H, Zhao SG, Tosoian JJ, Haddad Z, Takhar M, Chang SL, Spratt DE, Abdollah F, Jenkins RB, Klein EA, Nguyen PL, Dicker AP, Den RB, Davicioni E, Feng FY, Lotan TL, Schaeffer EM.

Clin Cancer Res. 2018 Aug 15;24(16):3908-3916. doi: 10.1158/1078-0432.CCR-17-2745. Epub 2018 May 14.

PMID:
29760221
29.

Contemporary Statewide Practice Pattern Assessment of the Palliative Treatment of Bone Metastasis.

Spratt DE, Mancini BR, Hayman JA, Boike T, Pierce LJ, Moran JM, Dominello MM, Fireman M, Griffith K, Jolly S; Michigan Radiation Oncology Quality Consortium.

Int J Radiat Oncol Biol Phys. 2018 Jun 1;101(2):462-467. doi: 10.1016/j.ijrobp.2018.02.037. Epub 2018 Mar 6.

PMID:
29726364
30.

Radical Prostatectomy, External Beam Radiotherapy, or External Beam Radiotherapy With Brachytherapy Boost and Disease Progression and Mortality in Patients With Gleason Score 9-10 Prostate Cancer.

Kishan AU, Cook RR, Ciezki JP, Ross AE, Pomerantz MM, Nguyen PL, Shaikh T, Tran PT, Sandler KA, Stock RG, Merrick GS, Demanes DJ, Spratt DE, Abu-Isa EI, Wedde TB, Lilleby W, Krauss DJ, Shaw GK, Alam R, Reddy CA, Stephenson AJ, Klein EA, Song DY, Tosoian JJ, Hegde JV, Yoo SM, Fiano R, D'Amico AV, Nickols NG, Aronson WJ, Sadeghi A, Greco S, Deville C, McNutt T, DeWeese TL, Reiter RE, Said JW, Steinberg ML, Horwitz EM, Kupelian PA, King CR.

JAMA. 2018 Mar 6;319(9):896-905. doi: 10.1001/jama.2018.0587.

31.

Patient-Reported Sexual Aid Utilization and Efficacy After Radiation Therapy for Localized Prostate Cancer.

Dess RT, Devasia TP, Aghdam N, Jackson WC, Soni PD, Smith CP, Mitchell AL, Suy S, Hamstra DA, Jolly S, Nguyen PL, Feng FY, Schipper MJ, Skolarus TA, Miller DC, Wittmann DA, Collins SP, Spratt DE.

Int J Radiat Oncol Biol Phys. 2018 Jun 1;101(2):376-386. doi: 10.1016/j.ijrobp.2018.01.055. Epub 2018 Jan 31.

PMID:
29487023
32.

Improving Quality and Consistency in NRG Oncology Radiation Therapy Oncology Group 0631 for Spine Radiosurgery via Knowledge-Based Planning.

Younge KC, Marsh RB, Owen D, Geng H, Xiao Y, Spratt DE, Foy J, Suresh K, Wu QJ, Yin FF, Ryu S, Matuszak MM.

Int J Radiat Oncol Biol Phys. 2018 Mar 15;100(4):1067-1074. doi: 10.1016/j.ijrobp.2017.12.276. Epub 2018 Jan 4.

PMID:
29485048
33.

Clinical and Genomic Characterization of Low-Prostate-specific Antigen, High-grade Prostate Cancer.

Mahal BA, Yang DD, Wang NQ, Alshalalfa M, Davicioni E, Choeurng V, Schaeffer EM, Ross AE, Spratt DE, Den RB, Martin NE, Mouw KW, Orio PF 3rd, Choueiri TK, Taplin ME, Trinh QD, Feng FY, Nguyen PL.

Eur Urol. 2018 Aug;74(2):146-154. doi: 10.1016/j.eururo.2018.01.043. Epub 2018 Feb 22.

PMID:
29478736
34.

Changes in prostate orientation due to removal of a Foley catheter.

Litzenberg DW, Muenz DG, Archer PG, Jackson WC, Hamstra DA, Hearn JW, Schipper MJ, Spratt DE.

Med Phys. 2018 Apr;45(4):1369-1378. doi: 10.1002/mp.12830. Epub 2018 Mar 25.

PMID:
29474748
35.

Standard dose and dose-escalated radiation therapy are associated with favorable survival in select elderly patients with newly diagnosed glioblastoma.

Jackson WC, Tsien CI, Junck L, Leung D, Hervey-Jumper S, Orringer D, Heth J, Wahl DR, Spratt DE, Cao Y, Lawrence TS, Kim MM.

J Neurooncol. 2018 May;138(1):155-162. doi: 10.1007/s11060-018-2782-z. Epub 2018 Feb 1.

PMID:
29388034
36.

Detailed pathologic analysis on the co-occurrence of non-seminomatous germ cell tumor subtypes in matched orchiectomy and retroperitoneal lymph node dissections.

Spratt DE, Suresh K, Osawa T, Schipper M, Jackson WC, Abugharib A, Lebastchi A, Smith D, Montgomery JS, Palapattu GS, Priya Kunju L, Wu A, Lew M, Tomlins SA, Chinnaiyan AM, Weizer AZ, Hafez KS, Kaffenberger SD, Udager A, Mehra R.

Med Oncol. 2018 Jan 31;35(3):21. doi: 10.1007/s12032-018-1090-y.

PMID:
29387987
37.

Comparison Between Adjuvant and Early-Salvage Postprostatectomy Radiotherapy for Prostate Cancer With Adverse Pathological Features.

Hwang WL, Tendulkar RD, Niemierko A, Agrawal S, Stephans KL, Spratt DE, Hearn JW, Koontz BF, Lee WR, Michalski JM, Pisansky TM, Liauw SL, Abramowitz MC, Pollack A, Moghanaki D, Anscher MS, Den RB, Zietman AL, Stephenson AJ, Efstathiou JA.

JAMA Oncol. 2018 May 10;4(5):e175230. doi: 10.1001/jamaoncol.2017.5230. Epub 2018 May 10.

PMID:
29372236
38.

Intermediate Endpoints After Postprostatectomy Radiotherapy: 5-Year Distant Metastasis to Predict Overall Survival.

Jackson WC, Suresh K, Tumati V, Allen SG, Dess RT, Salami SS, George A, Kaffenberger SD, Miller DC, Hearn JWD, Jolly S, Mehra R, Hollenbeck BK, Palapattu GS, Schipper M, Feng FY, Morgan TM, Desai NB, Spratt DE.

Eur Urol. 2018 Oct;74(4):413-419. doi: 10.1016/j.eururo.2017.12.023. Epub 2018 Jan 3.

PMID:
29306514
39.

A multi-institutional phase 2 trial of prostate stereotactic body radiation therapy (SBRT) using continuous real-time evaluation of prostate motion with patient-reported quality of life.

Jackson WC, Dess RT, Litzenberg DW, Li P, Schipper M, Rosenthal SA, Chang GC, Horwitz EM, Price RA, Michalski JM, Gay HA, Wei JT, Feng M, Feng FY, Sandler HM, Wallace RE, Spratt DE, Hamstra DA.

Pract Radiat Oncol. 2018 Jan - Feb;8(1):40-47. doi: 10.1016/j.prro.2017.08.004. Epub 2017 Aug 16.

PMID:
29304991
40.

Androgen deprivation therapy and risk of rheumatoid arthritis in patients with localized prostate cancer.

Yang DD, Krasnova A, Nead KT, Choueiri TK, Hu JC, Hoffman KE, Yu JB, Spratt DE, Feng FY, Trinh QD, Nguyen PL.

Ann Oncol. 2018 Feb 1;29(2):386-391. doi: 10.1093/annonc/mdx744.

PMID:
29267861
41.

Performance of a Prostate Cancer Genomic Classifier in Predicting Metastasis in Men with Prostate-specific Antigen Persistence Postprostatectomy.

Spratt DE, Dai DLY, Den RB, Troncoso P, Yousefi K, Ross AE, Schaeffer EM, Haddad Z, Davicioni E, Mehra R, Morgan TM, Rayford W, Abdollah F, Trabulsi E, Achim M, Tapia ELN, Guerrero M, Karnes RJ, Dicker AP, Hurwitz MA, Nguyen PL, Feng FFY, Freedland SJ, Davis JW.

Eur Urol. 2018 Jul;74(1):107-114. doi: 10.1016/j.eururo.2017.11.024. Epub 2017 Dec 10.

PMID:
29233664
42.

Travel distance and stereotactic body radiotherapy for localized prostate cancer.

Mahal BA, Chen YW, Sethi RV, Padilla OA, Yang DD, Chavez J, Muralidhar V, Hu JC, Feng FY, Hoffman KE, Martin NE, Spratt DE, Yu JB, Orio PF 3rd, Nguyen PL.

Cancer. 2018 Mar 15;124(6):1141-1149. doi: 10.1002/cncr.31190. Epub 2017 Dec 12.

PMID:
29231964
43.

An integrated multidisciplinary algorithm for the management of spinal metastases: an International Spine Oncology Consortium report.

Spratt DE, Beeler WH, de Moraes FY, Rhines LD, Gemmete JJ, Chaudhary N, Shultz DB, Smith SR, Berlin A, Dahele M, Slotman BJ, Younge KC, Bilsky M, Park P, Szerlip NJ.

Lancet Oncol. 2017 Dec;18(12):e720-e730. doi: 10.1016/S1470-2045(17)30612-5. Review.

PMID:
29208438
44.

Development and Validation of a Novel Integrated Clinical-Genomic Risk Group Classification for Localized Prostate Cancer.

Spratt DE, Zhang J, Santiago-Jiménez M, Dess RT, Davis JW, Den RB, Dicker AP, Kane CJ, Pollack A, Stoyanova R, Abdollah F, Ross AE, Cole A, Uchio E, Randall JM, Nguyen H, Zhao SG, Mehra R, Glass AG, Lam LLC, Chelliserry J, du Plessis M, Choeurng V, Aranes M, Kolisnik T, Margrave J, Alter J, Jordan J, Buerki C, Yousefi K, Haddad Z, Davicioni E, Trabulsi EJ, Loeb S, Tewari A, Carroll PR, Weinmann S, Schaeffer EM, Klein EA, Karnes RJ, Feng FY, Nguyen PL.

J Clin Oncol. 2018 Feb 20;36(6):581-590. doi: 10.1200/JCO.2017.74.2940. Epub 2017 Nov 29.

PMID:
29185869
45.

Funding source, conflict of interest and positive conclusions in neuro-oncology clinical trials.

Moraes FY, Mendez LC, Taunk NK, Raman S, Suh JH, Souhami L, Slotman B, Weltman E, Spratt DE, Berlin A, Marta GN.

J Neurooncol. 2018 Feb;136(3):585-593. doi: 10.1007/s11060-017-2687-2. Epub 2017 Nov 21.

PMID:
29164521
46.

Multi-institutional Evaluation of Elective Nodal Irradiation and/or Androgen Deprivation Therapy with Postprostatectomy Salvage Radiotherapy for Prostate Cancer.

Ramey SJ, Agrawal S, Abramowitz MC, Moghanaki D, Pisansky TM, Efstathiou JA, Michalski JM, Spratt DE, Hearn JWD, Koontz BF, Liauw SL, Pollack A, Anscher MS, Den RB, Stephans KL, Zietman AL, Lee WR, Stephenson AJ, Tendulkar RD.

Eur Urol. 2018 Jul;74(1):99-106. doi: 10.1016/j.eururo.2017.10.009. Epub 2017 Nov 9.

PMID:
29128208
48.

Radiosurgery for Treatment of Renal Cell Metastases to Spine: A Systematic Review of the Literature.

Smith BW, Joseph JR, Saadeh YS, La Marca F, Szerlip NJ, Schermerhorn TC, Spratt DE, Younge KC, Park P.

World Neurosurg. 2018 Jan;109:e502-e509. doi: 10.1016/j.wneu.2017.10.011. Epub 2017 Oct 13. Review.

PMID:
29038086
49.

Modified risk stratification grouping using standard clinical and biopsy information for patients undergoing radical prostatectomy: Results from SEARCH.

Zumsteg ZS, Chen Z, Howard LE, Amling CL, Aronson WJ, Cooperberg MR, Kane CJ, Terris MK, Spratt DE, Sandler HM, Freedland SJ.

Prostate. 2017 Dec;77(16):1592-1600. doi: 10.1002/pros.23436. Epub 2017 Oct 10.

PMID:
28994485
50.

Utility of ERG Immunohistochemistry for Evaluation of Lymphovascular Invasion in Testicular Germ Cell Tumors: A Retrospective Pilot Study.

Udager AM, McHugh JB, Morgan TM, Spratt DE, Chinnaiyan AM, Mehra R.

Appl Immunohistochem Mol Morphol. 2017 Sep 29. doi: 10.1097/PAI.0000000000000597. [Epub ahead of print]

PMID:
28968266

Supplemental Content

Loading ...
Support Center